Biotage Ab Stock Performance
| BITGF Stock | USD 16.87 0.00 0.00% |
On a scale of 0 to 100, Biotage AB holds a performance score of 9. The firm shows a Beta (market volatility) of -0.69, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Biotage AB are expected to decrease at a much lower rate. During the bear market, Biotage AB is likely to outperform the market. Please check Biotage AB's variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and rate of daily change , to make a quick decision on whether Biotage AB's price patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Biotage AB are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly unfluctuating technical and fundamental indicators, Biotage AB reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 371.3 M | |
| Total Cashflows From Investing Activities | -341 M |
Biotage |
Biotage AB Relative Risk vs. Return Landscape
If you would invest 1,200 in Biotage AB on January 25, 2024 and sell it today you would earn a total of 487.00 from holding Biotage AB or generate 40.58% return on investment over 90 days. Biotage AB is currently producing 0.6546% returns and takes up 5.1541% volatility of returns over 90 trading days. Put another way, 45% of traded otc stocks are less volatile than Biotage, and 88% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Biotage AB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biotage AB's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Biotage AB, and traders can use it to determine the average amount a Biotage AB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.127
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BITGF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.15 actual daily | 45 55% of assets are more volatile |
Expected Return
| 0.65 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average Biotage AB is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biotage AB by adding it to a well-diversified portfolio.
Biotage AB Fundamentals Growth
Biotage OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Biotage AB, and Biotage AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biotage OTC Stock performance.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.16 % | |||
| Current Valuation | 1.17 B | |||
| Shares Outstanding | 65.98 M | |||
| Price To Earning | 47.58 X | |||
| Price To Book | 6.36 X | |||
| Price To Sales | 6.61 X | |||
| Revenue | 1.23 B | |||
| EBITDA | 347 M | |||
| Cash And Equivalents | 15.1 M | |||
| Cash Per Share | 0.23 X | |||
| Total Debt | 150 M | |||
| Debt To Equity | 0.16 % | |||
| Book Value Per Share | 1.17 X | |||
| Cash Flow From Operations | 353 M | |||
| Earnings Per Share | 0.35 X | |||
| Total Asset | 1.99 B | |||
| Retained Earnings | 541 M | |||
| Current Asset | 327 M | |||
| Current Liabilities | 115 M | |||
About Biotage AB Performance
To evaluate Biotage AB OTC Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Biotage AB generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Biotage OTC Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Biotage AB market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Biotage's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Biotage AB provides separation technologies in the areas of organic and analytical chemistry, biomolecules, and industrial scale up applications. Biotage AB was founded in 1969 and is headquartered in Uppsala, Sweden. Biotage Ab is traded on OTC Exchange in the United States.Things to note about Biotage AB performance evaluation
Checking the ongoing alerts about Biotage AB for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Biotage AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biotage AB is way too risky over 90 days horizon | |
| Biotage AB appears to be risky and price may revert if volatility continues | |
| About 65.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Biotage AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biotage AB's stock is overvalued or undervalued compared to its peers.
- Examining Biotage AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biotage AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biotage AB's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Biotage AB's otc stock. These opinions can provide insight into Biotage AB's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biotage AB. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Biotage AB information on this page should be used as a complementary analysis to other Biotage AB's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Biotage OTC Stock analysis
When running Biotage AB's price analysis, check to measure Biotage AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotage AB is operating at the current time. Most of Biotage AB's value examination focuses on studying past and present price action to predict the probability of Biotage AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotage AB's price. Additionally, you may evaluate how the addition of Biotage AB to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |